Professor Daniel Rea

Professor Daniel Rea

Institute of Cancer and Genomic Sciences
Deputy Clinical Director – Late Phase Adult Solid Tumour
Professor of Medical Oncology

Contact details

Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Dr Rea is a Medical Oncologist with a primary Research Interest in Breast Cancer.


  • FRCP London   2003
  • PhD in Molecular Pathology University of London   1998
  • MBBS Medicine and Surgery University of London   1986 
  • BSc (Hons)   Animal Physiology University of Bristol     1983


Dr Rea is deputy Director of the Cancer Research UK Clinical Trials unit with responsibility for the phase III trials activity of the unit.

The current portfolio of late phase trials includes multiple tumour sites. The trials unit has produced a number of trials over the past decade that have directly impacted on clinical practice as well as improve our understanding of the treatment of a wide range of malignancies.

His own interests are in breast cancer research. He is the Chief Investigator for the aTTom Trial which has recently reported results demonstrating the clinical importance of prolonged adjuvant tamoxifen for early breast cancer and the TEAM study which has prospectively established the value of different hormonal strategies. Recent translational studies from this International Trial have provided statistically robust data to understand the relationship between hormone receptor, HER1-3 expression and differential endocrine sensitivity.

Further translational work is being conducted to evaluate the importance of many pathway abnormalities and their relationship to hormonal sensitivity. New Breast Cancer studies an exploration of biomarker driven chemotherapy selection in neoadjuvant chemotherapy and a trial to establish the safety of observation rather than immediate surgery for low grade ductal carcinoma in situ.

Dr Rea plays an active role in teaching lecturing on BSc BMed Sci and MSc courses and has arrange of teaching responsibilities for the both Undergraduate and postgraduate medicine. Dr Rea has Clinical responsibilities leading the Medical Oncology Service for breast Cancer at University Hospital Birmingham and Sandwell and West Birmingham NHS trust.


  • BMed Sci
  • MSc Oncology
  • Medicine


  • Chief Investigator for aTTom study
  • Chief Investigator for TEAM study
  • Chief Investigator for ROSCO study
  • Deputy lead Neoexell study
  • Deputy Lead LORIS study
  • Deputy lead MA 32 study
  • Co applicant Optima trial

Other activities

  • NCRI Breast Cancer Clinical studies group
  • Association of Cancer Physicians
  • British Breast Group
  • American Society of Clinical Oncology
  • European Society for Medical Oncology
  • British Medical Association
  • Fellow Royal College of Physicians
  • DMC member


JS Pascoe, D Palmer, D Spooner, DW Rea, SA Hussain (2009) 'Genomics and pharmacogenomics in the management of breast cancer'. Current Pharmacogenomics 6 45-55

SA Hussain, D Palmer, DE Swinson, P Riley, A Wills, C Brown, C Draycott, A El-Modir, DR Peake, DW Rea, AD Chetiyawardana, MH Cullen (2008) 'A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting'. Oncology reports 20 233-7

SA Hussain, DW Rea, D Palmer (2007) 'Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX'. British Journal of Cancer 96 1310-1310

SA Hussain, R Ganesan, GM Reynolds, L Gross, AJ Stevens, J Pastorek, PG Murray, B Perunovic, LJ Billingham, ND James, D Spooner, CJ Poole, DW Rea, D Palmer (2007) 'Hypoxia regulated Carbonic Anhydrase IX expression is associated with poor survival in patients with invasive breast cancer'. British Journal of Cancer 96 104-109

HC Routledge, DW Rea, RP Steeds (2007) 'Monitoring of cardiotoxicity during immunotherapy with Herceptin using simultaneous continuous wave Doppler depending on N-terminal pro-brain natriuretic peptide - In response'. Clinical medicine (London, England) 7 89-89

SA Hussain, D Palmer, D Spooner, DW Rea (2007) 'Molecularly targeted therapeutics for breast cancer'. BioDrugs 21 215-224

SA Hussain, DW Rea, ND James, D Palmer (2007) 'Signal transduction therapy: Challenges to Clinical Trial Design'. Current Signal Transduction Therapy 2 21-30

CJ Poole, HM Earl, L Hiller, JA Dunn, S Bathers, RJ Grieve, D Spooner, RK Agrawal, IN Fernando, AM Brunt, SM O'Reilly, SM Crawford, DW Rea, P Simmonds, JL Mansi, A Stanley, PG Harvey, K McAdam, L Foster, RCF Leonard, CJ Twelves (2006) 'Epirubicin and cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy for early breast cancer'. The New England Journal of Medicine 355 1851-1862

D Routledge, DW Rea, RP Steeds (2006) 'Monitoring the introduction of new drugs: Herceptin and cardiotoxicity'. Clinical Medicine 6 478-481

MH Cullen, NM Steven, LJ Billingham, CH Gaunt, M Hastings, P Simmonds, N Stuart, DW Rea, M Bower, IN Fernando, R Huddart, S Gollins (2005) 'Antibacterial prophylaxis after chemotherapy for solid tumours and lymphomas'. The New England Journal of Medicine 353 988-998

SA Hussain, D Palmer, A Stevens, D Spooner, CJ Poole, DW Rea (2005) 'Role of chemotherapy in breast cancer'. Expert Reviews on Anticancer Therapy 5 1095-1110

SA Hussain, D Palmer, S Moon, DW Rea (2004) 'Endocrine therapy and other targeted therapies for metastatic breast cancer'. Expert Review of Anticancer Therapy 4 1-17

SA Hussain, S Williams, A Stevens, DW Rea (2004) 'Endocrine therapy for early breast cancer'. Expert Review of Anticancer Therapy 4 877-888

DW Rea, L Hiller, HM Earl, JA Dunn, S Bathers, D Spooner, RK Agrawal (2004) 'Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: a non-radnomised comparison of patients treated in the NEAT trial'. Proceedings of the American Society of Clinical Oncology 23 595

G Caine, PS Stonelake, DW Rea, GYH Lip (2003) 'Coagulopathic complications in breast cancer'. Cancer 98 1578-1586

CJ Kirk, RM Harris, DM Wood, L Bottomley, DW Rea, PJ Hughes, RH Waring (2002) 'Environmental oestrogens: their role in testicular dysgenesis and hormone-dependent cancers'. Comparative Biochemistry & Physiology 132 S2

CJ Kirk, RM Harris, DM Wood, PJ Hughes, D Anderson, DW Rea, RH Waring (2001) 'Dietary phytoestrogens influence susceptibility to breast cancer by inhibiting sulphotransferase enzymes?' HEALFO Conference 'Food and Nutrition for Better Health, Lanciano, Italy 82

View all publications in research portal